الرئيسية » أرشيف الكاتب: tifwp

أرشيف الكاتب: tifwp

A NORMAL LIFE by Miriam Lauria

  “My name is Miriam and I live in the province of Matera, Italy. I have been suffering from thalassaemia major since birth. At the age of one year I began to receive blood transfusions every 15/18 days. Many people have this type of disease in a more or less ...

أكمل القراءة »

LOVING LIFE ENOUGH by Mary Manachi

This is the story of the late Mrs. Mary Manachi from New Jersey, USA, who lost 3 children from thalassaemia back in the 50’s-60’s, when no drugs and medical treatments were available to help prevent their death at a fairly young age. Mrs. Manachi passed away a few years ago, ...

أكمل القراءة »

High level Thalassaemia & SCD Healthcare Professionals Summit, Τhessaloniki, Greece – 1-2 November 2019

  Intensifying its long-standing efforts to provide constructive training to both thalassaemia and other haemoglobinopathy patients and to the specialized physicians working in these fields, TIF has successfully hosted a two-day High level Thalassaemia & Sickle Cell Healthcare Professionals Summit on 1 & 2 November 2019, in Thessaloniki, Greece. The ...

أكمل القراءة »

Capacity, Competence & Confidence: Building the three CS for patients’ organizations – Hamburg, Germany – 12-13 October 2019

Aiming at the continuous training of patients on issues relevant to the management of thalassaemia and other haemoglobinopathies, as well as the improvement of existing conditions and services provided for the support and care of patients with such diseases in Europe, TIF organized a multidisciplinary Capacity Building Workshop aimed at ...

أكمل القراءة »

Rapamycin

  Update: 25 November 2019 No update available.   Update: 27 September 2019 Rapamycin, a drug widely used for almost 20 years to protect organ transplant patients, has been found to reduce, in mice, the build up of toxic proteins that destroy red blood cells in β-thalassaemia. Investigators are moving ...

أكمل القراءة »

Mitapivat (AG-348)

  Update: 25 November 2019 No update available.   Update: 27 September 2019 DRIVE PK is an ongoing global, open-label, Phase 2, safety and efficacy study evaluating Mitapivat in adults with PK deficiency who do not receive regular transfusions. It is the first clinical trial in adults with PK deficiency. ...

أكمل القراءة »

FIGHTING WITH HOPE by Bidhan Sarkar

Winner Story #3 – International Thalassaemia Day 2019   ”I was born in a small village in Bangladesh. Four years later, one renowned child specialist diagnosed me as E-beta thalassaemia and gave a prognosis that my life span would be 15 to 20 years old. My parents at that time ...

أكمل القراءة »